Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.

Anaplastic thyroid cancer (ATC) is a locally aggressive type of thyroid tumor with high rate of distant metastases. It is often incurable because it does not respond to radioiodine, radiotherapy, or chemotherapy. With conventional treatment, the median survival is about 6 months; therefore, new treatment options are needed. S100A4 is a calcium-binding protein related to the metastatic potential of carcinoma. Previous study has found S100A4 was overexpressed in human papillary thyroid carcinomas (PTC) tissues, and overexpression of S100A4 is associated with thyroid tumour invasion and metastasis. In the present study, we first examined S100A4 protein expression in 14 ATC tissues, 20 PTC tissues and 14 normal thyroid tissue by immunohistochemistry analysis. We then knocked down of S100A4 expression by RNA interference (S100A4 siRNA) and investigated its effects on growth and metastasis in two human ATC cell lines 8505C (BRAFV600E) and Cal-62 (BRAFwt) in vitro and in vivo. S100A4 and BRAFV600E protein expression was evaluated by western blot assay and immunohistochemistry analysis. Using immunohistochemistry, we found that high levels of S100A4 were detected in ATC specimens and PTC specimens. No S100A4 staining was observed in normal thyroid tissues. S100A4 siRNA significantly decreased proliferation and increased apoptosis, and inhibited the invasive potential of the two cells in vitro. In addition, S100A4 siRNA could effectively inhibit BRAFV600E expression in the 8505C cells, and treatment with 100 ng/ml human recombinant BRAF V600E in S100A4 siRNA/8505C cells could partly restore its proliferative and invasive ability. Results of implantation in vivo showed S100A4 shRNA could significantly inhibit abdominal cavity metastasis and tumor growth in vivo. Furthermore, knockdown of S100A4 has significant role on invasion, metastasis and growth inhibition in the 8505C cells than that of in the Cal-62 cells. These results support the hypothesis that S100A4 contributes significantly to growth and metastasis, and that down-regulation of S100A4 expression decreases the metastatic potential of ATC cells. Furthermore, down-regulation of S100A4 expression is more marked in BRAFV600E cells than that of in the BRAFwt cells.

[1]  F. Pacini.  Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria. , 2008, Thyroid : official journal of the American Thyroid Association.

[2]  T. Ochiya,et al.  Silencing of S100A4, a metastasis-associated protein, in endothelial cells inhibits tumor angiogenesis and growth , 2013, Angiogenesis.

[3]  H. Min,et al.  S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid , 2008, Modern Pathology.

[4]  E. Hovig,et al.  Activation of NF‐κB by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes , 2008, International journal of cancer.

[5]  C. Heizmann,et al.  Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. , 2000, International journal of oncology.

[6]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[7]  G. Mælandsmo,et al.  Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-κB , 2010, BMC Cancer.

[8]  Shohreh Varmeh,et al.  Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer , 2014, Oncotarget.

[9]  M. Zou,et al.  Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  N. Wada,et al.  Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. , 2007, Anticancer research.

[11]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[12]  W. Park,et al.  Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  O. T. Odegaard,et al.  S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. , 1999, Cancer research.

[14]  David J Weber,et al.  S100A4, a Mediator of Metastasis* , 2006, Journal of Biological Chemistry.

[15]  A. Miyauchi,et al.  S100A4 Expression Is an Early Event of Papillary Carcinoma of the Thyroid , 2005, Oncology.

[16]  T. Okamoto,et al.  Phosphoinositide 3‐kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo , 2009, Cancer science.

[17]  A. Shaha,et al.  Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches , 2006, Annals of Surgical Oncology.

[18]  Kyung-Hee Kim,et al.  Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. , 2004, Yonsei medical journal.

[19]  S. Mishra,et al.  S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence , 2011, Cancer and Metastasis Reviews.

[20]  Z. Ye,et al.  High-Level Expression of S100A4 Correlates with Lymph Node Metastasis and Poor Prognosis in Patients with Gastric Cancer , 2009, Annals of Surgical Oncology.

[21]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[22]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yutaka Yamamoto,et al.  Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells , 2006, Cancer Chemotherapy and Pharmacology.

[25]  J. Cameron,et al.  Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. , 2002, The American journal of pathology.

[26]  M. Gao,et al.  Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma , 2009, Annals of Surgical Oncology.

[27]  Hasnah Hashim,et al.  S100A4 overexpression proves to be independent marker for breast cancer progression , 2008, Cancer Cell International.

[28]  Christopher Korch,et al.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  A. Fischer,et al.  Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer , 2011, The oncologist.

[30]  Seung‐Mo Hong,et al.  S100A4 expression is a prognostic indicator in small intestine adenocarcinoma , 2013, Journal of Clinical Pathology.

[31]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[32]  C. Larsson,et al.  Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. , 2007, Thyroid : official journal of the American Thyroid Association.

[33]  V. Detours,et al.  Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. , 2007, Cancer research.

[34]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[35]  T. Prolla,et al.  Novel approaches in anaplastic thyroid cancer therapy. , 2014, The oncologist.

[36]  H. Shan,et al.  An RGD-Modified MRI-Visible Polymeric Vector for Targeted siRNA Delivery to Hepatocellular Carcinoma in Nude Mice , 2013, PloS one.

[37]  M. Zou,et al.  Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[38]  M. Zou,et al.  S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma , 2005, British Journal of Cancer.

[39]  B. Zhivotovsky,et al.  S100A4 interacts with p53 in the nucleus and promotes p53 degradation , 2013, Oncogene.

[40]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[41]  Kjetil Boye,et al.  S100A4 and metastasis: a small actor playing many roles. , 2010, The American journal of pathology.